| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | zidesamtinib Adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 TKI | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology | |
PDUFA Date example | zidesamtinib Adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 TKI | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology | |
PDUFA Date example | zidesamtinib Adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 TKI | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Nuvalent, Inc.$123.9
+0.11 (+0.09%)
B 72Pipeline Score Fair Value Pharma · Clinical
Market Cap
8.07 B
EPS
-6.06
P/E Ratio
-
Value Trade
133.89 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
83.61 M
Operating CF
-92.40 M
Total Assets
1.33 B
Total Liabilities
156.78 M
Equity
1.17 B
D/E Ratio
12,345
-1.35 %
Week
-5.24 %
1 Month
-1.17 %
3 Month
-4.52 %
6 Month
464.2 %
5 Year
464.2 %
All Time
Cash Data
Cash Position
1.29 B
Monthly Burn
30.80 M
Runway
39.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.06 M
52 Week Range
70.25 - 113.02
% held by Insiders
31.66 %
% held by Institutions
82.33 %
Enterprise Value
6.78 B
Total Shares
67.26 M
Short %
6.21 %
Float Shares
46.81 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nuvalent, Inc.
320Total events
9Upcoming
55Tier-1 (high impact)
2021 – 2028Coverage
Upcoming catalysts 9
2026-H1
T1NDA Submission
NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC planned for first half of 2026
2026-H2
T2sNDA Submission
Planned submission of data to FDA for label expansion in TKI-naïve patients
2026-H2
T3Development Candidate Nomination
New development candidate nomination from discovery portfolio
Event history 311
Q3 2026
◆NDA SubmissionZidesamtinibRegulatory Filing
Submission for potential indication expansion of zidesamtinib in TKI-naive ROS1-positive NSCLC
TKI-naive advanced ROS1-positive NSCLCsource ↗
May 30, 2026
◆Poster PresentationZidesamtinibPresentation
Poster presentation of preliminary data for zidesamtinib in ROS1-positive solid tumors other than NSCLC at ASCO 2026
advanced ROS1-positive solid tumors other than NSCLCsource ↗
May 29, 2026
◆Oral PresentationNeladalkibPresentation
Pivotal data for neladalkib in TKI pre-treated advanced ALK+ NSCLC at ASCO 2026
ALK-positive non-small cell lung cancersource ↗
May 27, 2026
▲FDA Filing AcceptedNeladalkibRegulatory Filing
NDA for neladalkib accepted for filing with Priority Review
TKI pre-treated advanced ALK-positive NSCLCsource ↗
May 27, 2026
May 27, 2026
▲FDA Filing AcceptedZidesamtinibRegulatory Filing
NDA for zidesamtinib accepted for filing
TKI pre-treated advanced ROS1-positive NSCLCsource ↗
May 21, 2026
▲FDA Filing AcceptedZidesamtinibRegulatory Filing
FDA accepted NDA filing for zidesamtinib in ROS1-positive NSCLC
locally advanced or metastatic ROS1-positive NSCLC after at least 1 prior ROS1 TKIsource ↗
May 7, 2026
●NDA SubmissionNeladalkibRegulatory Filing
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
TKI pre-treated advanced ALK-positive NSCLCsource ↗
Apr 21, 2026
◆Poster PresentationZidesamtinibPresentation
Poster presentation: Zidesamtinib Has Differentiated Preclinical Brain Penetrance and Intracranial Activity Compared to Other ROS1 Inhibitors
ROS1-positive NSCLCsource ↗
Apr 21, 2026
▲FDA Filing AcceptedZidesamtinibRegulatory Filing
FDA accepted NDA submission for zidesamtinib in ROS1+ NSCLC
ROS1-positive non-small cell lung cancersource ↗
Drug Pipeline Intelligence
B72
Pipeline Score $13.2B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.6x
rNPV / MCap Top 95%
Small Cap (rank 47 of 911)
Percentile RankNuvalent, Inc. holds a solid B-grade pipeline (72/100), with $20.3B risk-adjusted pipeline value, led by Neladalkib in Locally Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neladalkib Small molecule | Non-small Cell Lung Cancer | Phase 3 | NCT06765109 | 87% | $9.4B | RECRUITING | 450 | VERY_FAST | C (59) | Dec 1, 2029 | MODERATE_RISK | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
neladalkib BreakthroughOrphan | advanced ALK-positive NSCLC | Phase 1/2 | 2026-05-21 | encouraging activity in TKI pre-treated patients | Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven... Read More | |
neladalkib BreakthroughOrphan | advanced ALK-positive NSCLC | Phase 1/2 | 2026-05-21 | encouraging activity in TKI pre-treated patients | Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven... Read More | |
neladalkib BreakthroughOrphan | advanced ALK-positive NSCLC | Phase 1/2 | 2026-05-21 | encouraging activity in TKI pre-treated patients | Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NUVL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NUVL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NUVL▲ +39.3%on this news
Stock-exchange announcement For media and investors only Issued: 9 June 2026, London UK GSK enters agreement to acquire Nuvalent, Inc. Multi-product oncology deal for assets that have validated targets and aim to address
GSK plc has announced its agreement to acquire Nuvalent, Inc. for $10.6 billion, which aligns with its strategy to enhance its oncology portfolio. This acquisition includes potentially best-in-class therapies for non-small cell lung cancer (NSCLC) that have garnered FDA Breakthrough Therapy and Orphan Drug designations. Besides promising immediate revenue generation and profit boosts, GSK aims to leverage Nuvalent's precision medicine capabilities. The transaction is subject to regulatory approvals and customary closing conditions.
Read more →NUVLNuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
Nuvalent, Inc. announced the acceptance of its New Drug Application for neladalkib by the FDA, which has been granted Priority Review with a target action date of November 27, 2026. The company has also appointed Georg Pirmin Meyer as Chief International Officer to lead its global expansion strategy. This comes as Nuvalent prepares for multiple product launches in biomarker-driven non-small cell lung cancer (NSCLC).
Read more →NUVLNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. is set to present pivotal data for neladalkib, an ALK-selective inhibitor, during the 2026 ASCO Annual Meeting, highlighting its support for a recent NDA submission. The results from the ALKOVE-1 trial indicate encouraging activity in TKI pre-treated patients with advanced ALK-positive NSCLC. Preliminary data for zidesamtinib, a ROS1-selective inhibitor, will also be showcased, reflecting potential benefits for patients with advanced ROS1-positive solid tumors other than NSCLC. Both presentations are significant steps toward Nuvalent's goal of improving treatment options for these cancer patient populations.
Read more →NUVLNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
Nuvalent, Inc. has made significant progress in its pipeline, submitting NDAs for neladalkib and zidesamtinib for advanced NSCLC. The company anticipates key regulatory milestones and is preparing for potential product launches in 2026. Additionally, Nuvalent has strengthened its leadership team to support its growth strategy.
Read more →NUVLNuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Nuvalent, Inc. will present pivotal data from the ALKOVE-1 trial for neladalkib, an ALK-selective inhibitor, at the 2026 ASCO Annual Meeting. Additionally, preliminary data for zidesamtinib in advanced ROS1-positive solid tumors will also be shared. Both drugs aim to address resistance in cancer treatments and have received breakthrough therapy designations from the FDA.
Read more →NUVLNew Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has presented promising data for its investigational drug zidesamtinib, a ROS1-selective inhibitor, at the AACR Annual Meeting 2026. The drug demonstrated meaningful activity in patients with ROS1-positive non-small cell lung cancer (NSCLC) who had been heavily pre-treated with other therapies. Notably, it showed efficacy against the ROS1 G2032R resistance mutation and exhibited intracranial responses in patients with CNS disease. The company is anticipating FDA approval for zidesamtinib, with a new drug application target action date set for September 2026.
Read more →NUVLNuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent, Inc. has submitted a New Drug Application (NDA) to the FDA for neladalkib, an investigational ALK-selective inhibitor for advanced ALK-positive NSCLC patients previously treated with TKIs. The submission is based on promising data from the ALKOVE-1 Phase 1/2 clinical trial, which demonstrated significant activity and a favorable safety profile. The company aims to expedite the review process to bring this therapy to patients quickly.
Read more →NUVLNuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
Nuvalent, Inc. announced the presentation of new preclinical and clinical data for zidesamtinib, a ROS1-selective inhibitor, at the AACR Annual Meeting 2026. The data will focus on patients with ROS1-positive NSCLC who were previously treated with other TKIs. Zidesamtinib aims to address limitations of existing therapies and has received FDA breakthrough therapy designation.
Read more →NUVLNuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Nuvalent, Inc. has outlined significant pipeline advancements and reiterated key milestones for 2026, including the potential U.S. launch of zidesamtinib and NDA submission for neladalkib. The company is focused on commercial readiness and expanding treatment options for advanced NSCLC patients. Financial results indicate a strong position to support ongoing development efforts.
Read more →NUVLNuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Nuvalent, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, featuring CEO James Porter and CFO Alexandra Balcom. The event is scheduled for February 12, 2026, at 1:30 p.m. ET in New York City. A live webcast will be available on the company's website, with an archived version accessible for 30 days post-event.
Read more →NUVL▲ +6.6%on this news
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDU
Nuvalent has made significant progress in its OnTarget 2026 operating plan, highlighted by the FDA's acceptance of the New Drug Application (NDA) for zidesamtinib, aimed at treating TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The company has outlined key milestones for 2026, including plans for a commercial launch of zidesamtinib and an NDA submission for neladalkib. With approximately $1.4 billion in cash, Nuvalent is well-positioned to support its development pipeline through 2029. Additionally, new treatments are being developed to address unmet needs in NSCLC and improve patient outcomes.
Read more →NUVL▼ -5.6%on this newsshared move
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of...
Nuvalent has made significant progress under its OnTarget 2026 operating plan, including the FDA's acceptance of the NDA for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC. The company outlined key milestones for 2026, including a potential first U.S. launch if zidesamtinib receives approval by the FDA. Additionally, Nuvalent is well-capitalized, expecting its financial resources to last into 2029, supporting both its commercial and development activities. Future submissions for neladalkib and expansions for zidesamtinib are also planned for the upcoming year.
Read more →NUVLNuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced that CEO James Porter will present at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 13, 2026. The presentation will focus on the company's efforts in developing targeted therapies for cancer, specifically aimed at overcoming existing treatment limitations. Nuvalent continues to advance its pipeline which includes candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer. A live webcast of the presentation will be available on the company's website.
Read more →NUVLNuvalent Appoints Ron Squarer to Board of Directors
Nuvalent, Inc. has appointed Ron Squarer to its Board of Directors, bringing over 30 years of experience in oncology drug development. His expertise is expected to strengthen Nuvalent's preparations for the anticipated launch of zidesamtinib for ROS1-positive non-small cell lung cancer in 2026. Squarer has a proven track record in advancing oncology therapeutics and commercialization.
Read more →NUVLNuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nuvalent, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat, highlighting the company's focus on targeted cancer therapies. A live webcast will be available for investors.
Read more →NUVLNuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. has successfully closed its public offering of 4,950,496 shares of Class A common stock, raising approximately $500 million. The offering, priced at $101.00 per share, was completed on November 20, 2025. Additionally, underwriters exercised their option to purchase 742,574 additional shares from selling stockholders, which closed on November 24, 2025.
Read more →NUVLNuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent, Inc. has announced that the FDA has accepted its New Drug Application for zidesamtinib, aimed at treating patients with advanced ROS1-positive non-small cell lung cancer who have previously received at least one ROS1 TKI. The application is based on data from the global ARROS-1 Phase 1/2 clinical trial, with a PDUFA target action date set for September 18, 2026. Zidesamtinib is designed to address limitations of existing therapies and has received breakthrough therapy designation.
Read more →NUVLNuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent, Inc. has announced the pricing of a public offering of its Class A common stock at $101.00 per share, aiming to raise approximately $500 million. The offering will close on November 20, 2025, pending customary closing conditions. Additionally, selling stockholders have granted underwriters a 30-day option to purchase more shares. Nuvalent is focused on developing targeted therapies for cancer.
Read more →NUVL▲ +11.9%on this newsshared move
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Nuvalent announced positive topline data from the ALKOVE-1 clinical trial for neladalkib, an ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive NSCLC. The results indicate a promising objective response rate and durability of response, with additional encouraging data from TKI-naïve patients. The company plans to discuss these findings with the FDA for potential registration.
Read more →NUVL▲ +11.9%on this newsshared move
Nuvalent Announces Public Offering of Common Stock Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced a public offering of its Class A common stock worth $500 million. The offering is subject to market conditions and the final terms will be disclosed later. While the company is advancing its pipeline focused on targeted cancer therapies, investors are advised to note that the offering's success is not guaranteed, and Nuvalent itself will not benefit from the sales of shares by the Selling Stockholders.
Read more →NUVLNuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced a webcast and conference call scheduled for November 17, 2025, to discuss topline pivotal data from its ALKOVE-1 clinical trial involving the investigational ALK-selective inhibitor neladalkib. This drug targets advanced ALK-positive non-small cell lung cancer (NSCLC) in patients previously treated with ALK tyrosine kinase inhibitors. Neladalkib is designed to penetrate the brain and address treatment resistance, and it has received FDA breakthrough therapy designation. The ALKOVE-1 trial continues to enroll participants globally, signifying ongoing research into this therapy's effectiveness.
Read more →NUVLNuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Nuvalent, Inc. announced the presentation of patient-reported outcomes data from the Phase 2 portion of the ARROS-1 trial for zidesamtinib at the 2025 IASLC ASCO North America Conference. The trial focuses on ROS1-positive non-small cell lung cancer (NSCLC), showcasing both patient outcomes and pivotal efficacy and safety data. Zidesamtinib aims to address challenges faced by existing ROS1 inhibitors, particularly in patients with brain metastases.
Read more →NUVLNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Nuvalent, Inc. has made significant progress in its pipeline, completing the NDA submission for zidesamtinib for advanced ROS1-positive NSCLC. The company is also on track to report pivotal data for neladalkib by the end of 2025. Despite a strong financial position, Nuvalent reported a net loss for Q3 2025, highlighting the challenges of drug development.
Read more →NUVL▲ +5.9%on this news
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has presented preliminary data for neladalkib, an investigational ALK-selective inhibitor, at ESMO 2025. The results indicate encouraging activity in a cohort of advanced ALK-positive solid tumors beyond NSCLC, with a 44% objective response rate observed among 34 patients. The trial showed promising safety profiles, confirming neladalkib's potential for broader treatment applications in this patient population. Ongoing enrollment in the Phase 2 portion of the ALKOVE-1 trial reflects Nuvalent’s commitment to advancing this treatment.
Read more →NUVLNuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced it will present new preclinical data for its HER2-selective inhibitor, NVL-330, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025. The poster presentation will detail the preclinical intracranial activity of NVL-330, which is designed to target HER2 effectively. The conference presents an opportunity to showcase this targeted therapy aimed at overcoming the limitations of existing cancer treatments. This development is part of Nuvalent's broader focus on creating innovative therapies for various cancer indications.
Read more →NUVLNuvalent to Participate in the UBS 2025 Virtual Oncology Day Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical firm focused on targeted cancer therapies, will take part in the UBS 2025 Virtual Oncology Day. CEO James Porter and CFO Alexandra Balcom are scheduled to participate in a fireside chat on October 1, 2025. A live webcast will be available on their website and can be accessed for 30 days afterward. The firm's commitment to addressing cancer through innovative drug design is underscored by its pipeline for various lung cancer types.
Read more →NUVLNuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. presented pivotal data from the ARROS-1 clinical trial for zidesamtinib, a novel ROS1-selective inhibitor targeting advanced ROS1-positive non-small cell lung cancer (NSCLC). This data supports Nuvalent's ongoing rolling New Drug Application submission to the FDA, aiming for completion in Q3 2025 under the Real-Time Oncology Review program. The drug is designed to provide new options for patients who have not responded to existing therapies, particularly those with brain metastases.
Read more →NUVLNuvalent to Participate in the Cantor Global Healthcare Conference 2025 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced its participation in the Cantor Global Healthcare Conference 2025, where CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat. The event is scheduled for September 4, 2025, at 9:45 a.m. ET in New York City. A live webcast will be available on the company's website and archived for 30 days. Nuvalent is focused on developing targeted therapies for cancer, particularly for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer.
Read more →NUVLNuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced the upcoming presentation of pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, at the IASLC 2025 World Conference on Lung Cancer. This data pertains to patients with advanced ROS1-positive non-small cell lung cancer who have been pre-treated with tyrosine kinase inhibitors. The company is also initiating a rolling NDA submission with the FDA, which has agreed to participate in the Real-Time Oncology Review program. Zidesamtinib aims to address resistance seen with existing therapies and offers potential CNS benefits for patients.
Read more →NUVL▼ -6.6%on this news
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third ...
Nuvalent, Inc. has initiated a rolling NDA submission for zidesamtinib aimed at TKI pre-treated patients with advanced ROS1-positive NSCLC. The company also commenced the ALKAZAR Phase 3 trial for neladalkib in TKI-naïve ALK-positive NSCLC. Financial results for Q2 2025 show a net loss of $99.7 million, but the company maintains a strong cash position to support future operations.
Read more →NUVL▼ -6.6%on this news
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patie
Nuvalent, Inc. has highlighted significant advancements in its pipeline and business achievements, emphasizing its rolling NDA submission for zidesamtinib aimed at TKI pre-treated patients with advanced ROS1-positive NSCLC. The company has also initiated a Phase 3 trial for neladalkib and expects to report pivotal data by the end of 2025. Additionally, Nuvalent reported its second quarter 2025 financial results, noting a net loss of $99.7 million but positive milestones that could enhance its position in the biopharma sector. Leadership changes, including the promotion of Jason Waters, suggest strategic growth efforts are underway.
Read more →NUVLNuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has initiated the ALKAZAR Phase 3 trial to evaluate neladalkib in patients with TKI-naïve ALK-positive NSCLC, marking a significant milestone in their clinical development program. The trial will compare neladalkib with alectinib, a standard treatment, with primary endpoints focused on progression-free survival. Darlene Noci, Nuvalent's Chief Development Officer, expressed optimism about neladalkib's potential to meet unmet medical needs, particularly for brain metastases. This trial aims to enroll around 450 patients and could pave the way for broader treatment options in advanced ALK-positive NSCLC.
Read more →NUVLNuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology...
Nuvalent, Inc. announced positive pivotal data for zidesamtinib, a ROS1-selective inhibitor, from the ARROS-1 clinical trial focused on TKI pre-treated patients with advanced ROS1-positive NSCLC. The FDA has agreed to participate in the Real-Time Oncology Review program, supporting an expedited NDA submission. The trial demonstrated significant efficacy with a high overall response rate and favorable duration of response. The study is expected to play a critical role in establishing zidesamtinib as a leading treatment option in this patient population.
Read more →NUVLNuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced a webcast scheduled for June 24, 2025, to discuss pivotal data from its ARROS-1 clinical trial for zidesamtinib, a drug targeting ROS1-positive non-small cell lung cancer. The trial specifically focuses on TKI pre-treated patients, aiming to demonstrate the drug's effectiveness in addressing resistance to existing ROS1 inhibitors. Zidesamtinib is designed with unique features that could enhance treatment outcomes and penetration into the central nervous system. This announcement highlights Nuvalent's ongoing efforts in cancer therapy development and its potential as an innovative treatment option.
Read more →NUVLNuvalent Appoints Christy Oliger to Board of Directors Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has appointed Christy Oliger to its Board of Directors, bringing over 30 years of experience in pharmaceuticals, particularly in oncology. This appointment comes as the company transitions from a development-stage entity to one poised for potential commercialization, with a target approval for its kinase inhibitors pipeline in 2026. Oliger's expertise is expected to bolster Nuvalent's focus on delivering targeted cancer therapies, although the company faces significant risks in clinical trials and regulatory approvals.
Read more →NUVL▲ +7.3%on this news
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-posi
Nuvalent, Inc. has outlined its recent progress in pipeline development and business operations, emphasizing significant milestones anticipated in 2025. The company is expecting pivotal data for its lead drug candidates, zidesamtinib and neladalkib, and aims to submit a New Drug Application (NDA) for zidesamtinib by mid-year 2025. Leadership changes aim to strengthen operational execution, while the company maintains a robust cash position to support ongoing development. However, it recorded a net loss of $84.6 million for the first quarter of 2025, highlighting ongoing financial challenges.
Read more →NUVL▲ +7.3%on this news
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has outlined significant progress in its pipeline, with pivotal data expected for zidesamtinib and neladalkib in 2025. The company is preparing for its first NDA submission for zidesamtinib and has initiated a Phase 3 trial for neladalkib. Recent leadership promotions highlight the strength of its team as it transitions towards becoming a commercial-stage biopharmaceutical company.
Read more →NUVLNuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced the publication of a manuscript in Molecular Cancer Therapeutics, supporting the molecular design of zidesamtinib, a selective ROS1 inhibitor. The publication showcases its potential effectiveness against ROS1 resistance mutations, particularly highlighting the first structure of the ROS1 G2032R mutation. Zidesamtinib aims to address tumors resistant to existing ROS1 inhibitors while minimizing adverse events related to centrally acting compounds. The company anticipates pivotal clinical data from the ARROS-1 Phase 1/2 trial for advanced ROS1-positive NSCLC in 2025.
Read more →NUVLNuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced the presentation of two Trial in Progress posters at the 2025 ASCO Annual Meeting. These posters detail the ALKAZAR trial for its ALK-selective inhibitor neladalkib, and the HEROEX-1 trial for NVL-330, a HER2-selective inhibitor. The ALKAZAR trial aims to compare neladalkib with the standard care for ALK-positive NSCLC, while HEROEX-1 will evaluate NVL-330’s safety and dosing in HER2-altered NSCLC. Both trials seek to provide targeted therapies for specific patient populations.
Read more →NUVLNuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced that its CEO James Porter and CFO Alexandra Balcom will participate in the Stifel 2025 Virtual Targeted Oncology Forum. The event is scheduled for April 8, 2025, and will feature a fireside chat format. The company, known for developing targeted therapies for cancer, aims to advance its innovative approaches and pipeline during this prominent industry event.
Read more →NUVLNuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced that it will present new preclinical data on its ALK-selective inhibitor, neladalkib, and ROS1-selective inhibitor, zidesamtinib, at the AACR Annual Meeting 2025. The poster presentations will highlight research supporting their potential as best-in-class candidates for treating cancer, particularly in overcoming resistance to existing therapies. Both drugs are designed to penetrate the central nervous system effectively and have received breakthrough therapy and orphan drug designations for specific indications.
Read more →NUVLNuvalent to Participate in Upcoming March Investor Conferences Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced its participation in upcoming investor conferences in March, with CEO James Porter and CFO Alexandra Balcom scheduled to engage in fireside chats. The company is noted for its dedication to developing targeted therapies for cancer, particularly against clinically proven kinase targets. Their pipeline includes promising candidates aimed at challenging current treatment limitations and improving patient outcomes. Live webcasts of the conferences will be available on their website, showcasing their ongoing commitment to transparency and investor relations.
Read more →NUVLNuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results Topline pivotal data expected in 2025 for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC populations First NDA submission...
Nuvalent, Inc. has outlined its pipeline progress and business updates, highlighting pivotal data expected in 2025 for TKI pre-treated ROS1-positive and ALK-positive NSCLC populations. The company plans to submit its first NDA by mid-2025 for zidesamtinib. Additionally, it has launched global Expanded Access Programs to enhance patient access. Despite a significant net loss reported for Q4 2024, Nuvalent maintains a robust cash position to support its operations.
Read more →NUVLNuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results Topline pivotal data expected in 2025 for both TKI pre-treated ROS1
Nuvalent, Inc. has outlined significant progress in its clinical pipeline and reaffirmed key upcoming milestones in its business strategy. The company anticipates pivotal data in 2025 for both TKI pre-treated ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC) populations. They plan their first NDA submission by mid-2025 for zidesamtinib, aimed at addressing unmet medical needs. Nuvalent has also reported robust financial results, with a cash position of $1.1 billion expected to fund operations through 2028. The launch of global Expanded Access Programs highlights their commitment to patient access while continuing to advance their research initiatives.
Read more →NUVL▼ -6.2%on this news
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has outlined its strategy for seeking FDA approval by 2026, focusing on zidesamtinib for ROS1-positive NSCLC. Key milestones include a New Drug Application submission by mid-2025 and pivotal data reporting for both zidesamtinib and neladalkib in 2025. The company is also preparing for a presentation at the J.P. Morgan Healthcare Conference.
Read more →NUVL▼ -6.2%on this news
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mi
Nuvalent Inc. has outlined its strategy to seek FDA approval for zidesamtinib by 2026, focusing on the TKI pre-treated ROS1-positive NSCLC market. The company expects to submit its initial NDA in mid-2025, along with topline pivotal data anticipated in the first half of the year. Additionally, the company plans to report pivotal data for neladalkib by the end of 2025. The advancement of these therapies aims to address significant medical needs in lung cancer treatment, particularly for patients with brain metastases.
Read more →NUVLNuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced that its CEO, James Porter, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will highlight Nuvalent's focus on creating targeted therapies for cancer, particularly for kinase targets. The company is actively developing investigational candidates for various types of lung cancer and has multiple research programs underway. A live webcast of the presentation will be available on the company's website.
Read more →NUVLNuvalent Appoints Grant Bogle to Board of Directors Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has appointed Grant Bogle to its Board of Directors to enhance its leadership as it aims for potential drug approvals in 2026. Bogle's extensive experience in oncology biotechnology is seen as a valuable addition during a pivotal transition from development to commercialization. The company is conducting multiple clinical trials, including its ARROS-1 and ALKOVE-1 programs, with key data expected in 2025. Nuvalent seeks to address critical challenges in cancer treatment through its innovative therapies targeting kinase mutations.
Read more →NUVLRESTRICTED STOCK UNIT AWARD AGREEMENT (PERFORMANCE-VESTING) FOR COMPANY EMPLOYEES UNDER THE NUVALENT, INC. 2021 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the
Nuvalent, Inc. has issued a Restricted Stock Unit Award Agreement under its 2021 Stock Option and Incentive Plan. This agreement pertains to performance-vesting for company employees and outlines the terms under which these stock units can be granted, vested, and issued. The agreement includes clauses on transfer restrictions, vesting conditions, termination of employment, tax withholding, and data privacy consent. Additionally, it is stated that the company is under no obligation to continue the employment of any grantee.
Read more →NUVLNuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL) will participate in the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024. CEO James Porter and CFO Alexandra Balcom are scheduled to engage in a fireside chat aimed at investors. The event provides a platform for Nuvalent to showcase its innovative approaches in developing targeted therapies for cancer, particularly addressing kinase targets. A live webcast of the presentation will be available on the company’s website.
Read more →NUVLNuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results Achievement of all anticipated 2024 milestones and accelerated development
Nuvalent, a clinical-stage biopharmaceutical company, announced significant achievements in its corporate and pipeline developments while reporting its third-quarter 2024 financial results. The company has met all of its anticipated milestones for 2024 and is on track towards its goal of having an approved product by 2026. They have a robust cash position of $1.2 billion, expected to sustain operations into 2028, and have appointed prominent oncologist Dr. Alice Shaw to its Scientific Advisory Board. The updates include promising clinical trial results for its novel kinase inhibitors aimed at targeting specific mutations in lung cancer.
Read more →NUVLNuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. reported significant progress in its pipeline and financial results for Q3 2024. The company achieved all its anticipated milestones for the year and has a strong cash position of $1.2 billion, extending its operational runway into 2028. Notably, leading oncologist Dr. Alice Shaw has joined its Scientific Advisory Board, enhancing its expertise in targeted therapies.
Read more →NUVLNuvalent Announces Pricing of Upsized Public Offering of Common Stock CAMBRIDGE, Mass., September 16 , 2024 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted
Nuvalent, Inc. has announced the pricing of an upsized public offering of 5 million shares of Class A common stock at $100 per share, aiming to raise approximately $500 million. The offering will close on September 18, 2024, pending customary closing conditions, and includes a 30-day option for underwriters to purchase additional shares. This capital is intended to support Nuvalent's development of targeted therapies for cancer, addressing areas such as ROS1-positive and ALK-positive non-small cell lung cancers. Notably, the offering is part of a registered shelf program with the SEC initiated in March 2023.
Read more →NUVLNuvalent Announces Closing of Upsized Public Offering of Common Stock Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has successfully closed an upsized public offering of 5,750,000 shares of Class A common stock, raising approximately $575 million. The offering price was set at $100.00 per share, with the underwriters exercising their option to purchase additional shares. The proceeds will support Nuvalent's mission to develop targeted therapies for various cancers, including ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer. The offering was executed under an effective shelf registration statement filed with the SEC.
Read more →NUVL▲ +28.3%on this newsshared move
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced the pricing of an upsized public offering of 5 million shares of Class A common stock at $100.00 per share, aiming to raise approximately $500 million in gross proceeds. The offering is scheduled to close on September 18, 2024, pending customary conditions. The shares are offered under a previously filed shelf registration statement with the SEC. A 30-day option for underwriters to purchase an additional 750,000 shares is also included.
Read more →NUVL▲ +28.3%on this newsshared move
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib...
Nuvalent presented updated Phase 1 data for its clinical trials on zidesamtinib and NVL-655 at the ESMO Congress 2024, highlighting their promising profiles in treating ROS1 and ALK-positive NSCLC. The company reported rapid enrollment in Phase 2 trials, with pivotal data anticipated in 2025. A Phase 3 trial for NVL-655 is scheduled to begin in early 2025, aiming to provide new treatment options for patients. The successful milestones achieved in 2024 are part of Nuvalent's strategy to expedite the development of these therapies.
Read more →NUVL▲ +28.3%on this newsshared move
One Broadway, 14 th Floor Cambridge, MA 02142 Nuvalent.com Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines U
Nuvalent presented updated clinical data at ESMO 2024 for its lead programs targeting ROS1 and ALK-positive NSCLC, showcasing favorable results from its Phase 1 trials. The company noted successful enrollment in Phase 2 trials and plans to initiate the ALKAZAR Phase 3 study for treatment-naive patients in 2025. Preliminary data indicates potential best-in-class profiles of zidesamtinib and NVL-655, with encouraging patient responses observed in heavily pre-treated populations. The anticipated pivotal results in 2025 are expected to aid in advancing treatment options for these patient groups.
Read more →NUVL▲ +7.1%on this news· ran to +37% by day 1shared move
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced the publication of a manuscript in Cancer Discovery detailing NVL-655, an ALK-selective inhibitor, and its promising preclinical and preliminary clinical results. The study highlights NVL-655's design for addressing drug resistance and improving tolerability in patients with advanced ALK-positive NSCLC. The ALKOVE-1 Phase 1/2 clinical trial is currently ongoing, aiming to explore the efficacy of NVL-655 in patients previously treated with other ALK inhibitors. These findings suggest NVL-655 could become a significant treatment option in ALK-positive oncology.
Read more →NUVLUpdated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. provided updates on its ALK-selective inhibitor NVL-655 and ROS1-selective inhibitor zidesamtinib based on Phase 1 trial data, set to be presented at ESMO Congress 2024. The data indicates durable responses in heavily pre-treated patients, supporting further Phase 2 investigations. The company plans a conference call to discuss these findings and the status of the studies. Both inhibitors have shown promise for improved outcomes in previously treated cancer patients.
Read more →NUVLNuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat, which will also be available via live webcast. The company, focused on developing targeted cancer therapies, aims to demonstrate its advancements in drug development for specific kinase targets. This event marks an important opportunity for Nuvalent to connect with investors and the broader healthcare community.
Read more →NUVLNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results Company plans to host a conference call in conjunction with oral presentations at ESMO on
Nuvalent, Inc. reported significant advancements in its clinical pipeline and financial results for Q2 2024, including FDA breakthrough therapy designations for NVL-655 and zidesamtinib. The company highlighted ongoing enrollment in the Phase 2 trials for both therapies aimed at treating advanced ALK-positive and ROS1-positive non-small cell lung cancer. With a strong cash position expected to sustain operations into 2027, Nuvalent is on schedule to present pivotal data by 2025, further outlining their development strategies during the upcoming ESMO Congress. However, the company also reported a net loss for the quarter, reflecting the inherent risks of drug development.
Read more →NUVLNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has reported significant progress in its clinical pipeline and financial results for Q2 2024. The company has initiated the Phase 2 trials for NVL-655 and zidesamtinib, both of which have received FDA breakthrough therapy designations. With a robust cash position, Nuvalent is well-positioned to advance its targeted therapies for cancer, aiming for pivotal data by 2025.
Read more →NUVLNuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced the first patient dose in the HEROEX-1 Phase 1a/1b clinical trial for NVL-330, a novel HER2-selective inhibitor. This trial aims to evaluate NVL-330's safety and efficacy in pre-treated patients with HER2-altered non-small cell lung cancer. The treatment seeks to address existing treatment gaps, particularly for patients with HER2 exon 20 mutations, and aims to minimize side effects associated with other HER2-targeting therapies. The CEO emphasized the milestone as part of the company’s broader strategy to develop precisely targeted therapies for cancer patients.
Read more →NUVLNuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced its plans to present updated data on its ROS1-selective inhibitor, zidesamtinib, and ALK-selective inhibitor, NVL-655, at the ESMO Congress 2024 in September. These presentations will include findings from ongoing Phase 1/2 trials for both drug candidates aimed at treating specific lung cancers. Both drugs are designed to overcome limitations of existing therapies, particularly in patients with advanced forms of the diseases. Additionally, new preclinical data on zidesamtinib's efficacy in targeting resistant tumors will also be showcased.
Read more →NUVLNuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced the promotion of Dr. Henry Pelish to Chief Scientific Officer, recognizing his substantial contributions to the company since its inception. In his new role, Dr. Pelish will oversee the discovery and early-stage development activities, where he has been instrumental in developing novel therapies aimed at overcoming the limitations of existing cancer treatments. Under his leadership, the company has advanced multiple investigational candidates with initial clinical proof-of-concept, enhancing its robust pipeline dedicated to targeted cancer therapies.
Read more →NUVLNuvalent to Participate in the 2024 Jefferies Global Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL) has announced that CEO James Porter and CFO Alexandra Balcom will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference. The event is scheduled for June 5, 2024, in New York City. A live webcast will be made available on Nuvalent's website and will remain accessible for 30 days after the presentation. This participation underscores Nuvalent's focus on developing therapies for cancer, particularly targeting clinically proven kinase pathways.
Read more →NUVLNuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced that its drug NVL-655 has received Breakthrough Therapy Designation from the U.S. FDA for treating patients with ALK-positive non-small cell lung cancer. This designation aims to expedite the development process due to the drug's potential to provide significant improvement over current therapies. NVL-655 targets ALK-rearranged cancers, particularly for patients who have been previously treated with multiple ALK inhibitors. The company intends to share updates from its ongoing ALKOVE-1 clinical trial later this year.
Read more →NUVLNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. reported progress in its clinical pipeline and financial results for Q1 2024. The company anticipates updates from its ARROS-1 and ALKOVE-1 trials at a medical meeting later this year. With a strong cash position expected to last until 2027, Nuvalent aims for its first product approval by 2026. The CEO emphasized focused execution on their OnTarget 2026 plan.
Read more →NUVLNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical
Nuvalent, Inc. has reported significant pipeline progress and reiterated key anticipated milestones alongside its first quarter 2024 financial outcomes. The company is focused on executing clinical trials for its novel kinase inhibitors, with pivotal data expected by 2025 and potential product approval planned for 2026. Updates on ongoing Phase 1/2 trials for ROS1-positive and ALK-positive NSCLC are anticipated during a medical meeting in the latter half of the year. With a cash position of approximately $691.8 million, Nuvalent is poised to fund its operations through 2027.
Read more →NUVLNuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. presented new preclinical data for its HER2-selective inhibitor NVL-330 and ROS1-selective inhibitor zidesamtinib (NVL-520) at the AACR Annual Meeting 2024. The results indicate that NVL-330 has significant activity against HER2 alterations while maintaining selectivity over wild-type EGFR. Zidesamtinib displayed efficacy in suppressing resistance mutations associated with ROS1. The company is also planning to initiate a Phase 1 trial for NVL-330 this year.
Read more →NUVLNuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. will present new preclinical data on its HER2-selective inhibitor, NVL-330, and ROS1-selective inhibitor, zidesamtinib (NVL-520) at the AACR Annual Meeting 2024. The presentations will detail the preclinical profiles of both compounds, highlighting NVL-330's ability to address HER2-mutant tumors and zidesamtinib's capability to overcome resistance in ROS1-positive tumors. Zidesamtinib has also received breakthrough therapy designation for ROS1-positive metastatic non-small cell lung cancer, signifying its potential in cancer treatment. The event is scheduled for April 5-10 in San Diego.
Read more →NUVLNuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has been granted Breakthrough Therapy Designation by the U.S. FDA for its investigational drug NVL-520, aimed at treating patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC). This designation expedites the development of therapies that may demonstrate significant improvement over existing treatments for life-threatening conditions. NVL-520 has shown preliminary safety and efficacy in heavily pretreated patients, addressing issues such as treatment resistance and brain metastases. The company plans to provide updates from the ongoing ARROS-1 trial in 2024.
Read more →NUVLNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. reported its fourth quarter and full year 2023 financial results, highlighting key pipeline advancements. The company has initiated the Phase 2 ALKOVE-1 study for NVL-655 and received FDA breakthrough therapy designation for NVL-520. With a strong cash position, Nuvalent aims for its first approved product by 2026, while also announcing leadership promotions.
Read more →NUVLNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. &
Nuvalent, Inc. has announced significant progress in its pipeline, highlighting the initiation of Phase 2 trials for NVL-655 and receipt of breakthrough therapy designation for NVL-520 in 2023. The company is well-capitalized, projecting to sustain its operations into 2027 with a cash position of $719.9 million. Key anticipated milestones include the sharing of updated data from ongoing trials and the expected initiation of the Phase 1 trial for its HER2 program in 2024. Leadership changes have also been introduced to strengthen its team as it moves towards potential product approvals by 2026.
Read more →NUVLNuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced the initiation of the Phase 2 portion of its ALKOVE-1 clinical trial for NVL-655, targeting patients with ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. This advancement follows FDA alignment on a recommended dose of 150 mg once daily. Designed with registrational intent, the trial will evaluate the treatment's efficacy in both TKI pre-treated and TKI-naïve patient populations. The company aims for NVL-655 to provide durable responses while minimizing adverse effects, supporting its broader goal of efficient therapeutic development.
Read more →NUVLNuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL) announced its upcoming participation in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The CEO, James Porter, and CFO, Alexandra Balcom, will engage in a fireside chat, reflecting the company's commitment to investor communication. Nuvalent specializes in developing targeted therapies for cancer, aiming to address existing treatment limitations. The event will include a live webcast accessible through the company’s website, with an archived version available for 30 days post-event.
Read more →NUVLNuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to pat
Nuvalent, Inc. has announced its 'OnTarget 2026' operating plan, aiming for its first potential FDA-approved product by 2026. The plan focuses on developing novel therapies targeting ROS1 and ALK mutations in NSCLC, with several milestones set for 2024 and pivotal data expected in 2025. The company reported $719.9 million in cash reserves, ensuring operational support into 2027. CEO James Porter highlighted a clear path towards achieving these objectives, demonstrating a strong commitment to patient needs and innovative cancer therapies.
Read more →NUVLNuvalent Announces OnTarget 2026 Operating Plan and Key Anticipated Milestones Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced its 'OnTarget 2026' operating plan with the aim of achieving its first potential FDA approval by 2026. The plan outlines key milestones, including pivotal data from lead clinical programs expected in 2025. With $719.9 million in cash as of year-end 2023, the company anticipates having the financial support necessary to execute this strategy through 2027. Furthermore, Nuvalent emphasizes its focus on developing therapies that target specific cancer mechanisms to improve patient outcomes.
Read more →NUVLNuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced that CEO James Porter will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will focus on the company's development of targeted cancer therapies aimed at overcoming limitations of existing treatments. Nuvalent has a strong pipeline, including lead programs for ROS1-positive and ALK-positive non-small cell lung cancer, as well as HER2 Exon 20 insertion-positive cancers. A live webcast of the presentation will be available on their website.
Read more →NUVLNuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. reported significant progress in its clinical pipeline and financial results for Q3 2023. The company presented preliminary Phase 1 data for NVL-655 and initiated the Phase 2 portion of the ARROS-1 trial for NVL-520. Additionally, Nuvalent raised $300 million through a public offering, extending its operational runway into 2027. Despite a net loss of $33.6 million, the company remains optimistic about its future developments.
Read more →NUVLNuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 tr
Nuvalent, Inc. announced its third quarter 2023 financial results and highlighted various achievements in its pipeline development. The company presented promising preliminary Phase 1 data for NVL-655 in patients with ALK-positive NSCLC and launched the Phase 2 portion of the ARROS-1 trial for NVL-520. Furthermore, Nuvalent completed a successful public offering, raising approximately $300 million, which positions the company to extend its operational runway into 2027. Leadership was also bolstered with the appointment of Dr. Perrin Wilson as Senior Vice President of Business Development and Strategy.
Read more →NUVLNuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, has announced its participation in the BMO Virtual BioPharma Spotlight Series: Oncology Day on November 8, 2023. CEO James Porter and CFO Alexandra Balcom will take part in a fireside chat as part of the event. The company is recognized for its focus on developing targeted therapies for kinase targets in cancer and has made significant advancements in its therapeutic pipeline. A live webcast of the chat will be accessible via the company's website.
Read more →NUVLNuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK- Positive NSCLC Encouraging preliminary signs of activity observed in heavily p
Nuvalent has reported preliminary data from the Phase 1 ALKOVE-1 clinical trial of NVL-655, a targeted therapy for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). Encouraging response rates were observed in a heavily pre-treated patient population, with an overall response rate of 39%. The trials showed that NVL-655 is well-tolerated, demonstrating a favorable safety profile. Ongoing enrollment and analysis aim to further understand the drug's potential in addressing treatment resistance and delays in disease progression.
Read more →NUVLNuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced promising preliminary data from the Phase 1 ALKOVE-1 trial of NVL-655, a novel ALK-selective inhibitor for ALK-positive NSCLC. The data showed a 39% objective response rate among heavily pre-treated patients, with a favorable safety profile. The company aims to transition to Phase 2 trials following further evaluations.
Read more →NUVL▲ +35.6%on this news· ran to +47% by day 1
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile Updated preliminary d
Nuvalent, Inc. announced preliminary data from the Phase 1 ALKOVE-1 trial evaluating NVL-655 in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The results demonstrated a promising objective response rate of 45% among heavily pre-treated patients. NVL-655 is designed to selectively target ALK fusions while avoiding common CNS adverse events associated with current therapies. Further evaluations on safety and efficacy will be presented at the upcoming AACR-NCI-EORTC Symposium.
Read more →NUVL▲ +35.6%on this news· ran to +47% by day 1
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced preliminary results from the Phase 1 dose-escalation of its ALKOVE-1 trial for NVL-655, targeting ALK-positive NSCLC. The data showed promising anti-tumor activity, particularly in heavily pre-treated patients, with a 45% objective response rate. The drug was well-tolerated, with mild adverse events reported. Further updates will be presented at the upcoming AACR-NCI-EORTC Symposium.
Read more →NUVL▼ -6.1%on this news
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent Inc. announced it will present preliminary data from its ongoing ALKOVE-1 Phase 1/2 trial of NVL-655, a selective ALK inhibitor. The presentation will take place at the upcoming AACR-NCI-EORTC Symposium in Boston, where they will share insights on the safety and clinical activity of NVL-655. This drug is specifically designed to address the challenges faced by current ALK tyrosine kinase inhibitors, including efficacy against resistance mutations and improved brain penetration. The trial continues to enroll patients, highlighting ongoing clinical development efforts by Nuvalent.
Read more →NUVLNuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has initiated the Phase 2 portion of the ARROS-1 clinical trial for its drug NVL-520, aimed at treating patients with ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. This follows the FDA's agreement on a recommended dose of 100 mg daily. The trial will explore NVL-520's efficacy and safety across multiple cohorts, targeting both treatment-naive and pre-treated patients. The drug is designed to penetrate the blood-brain barrier while potentially offering superior therapeutic benefits compared to existing treatments.
Read more →NUVLNuvalent to Participate in Upcoming September Investor Conferences Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced that its CEO James Porter and CFO Alexandra Balcom will participate in several investor conferences in September. The company focuses on developing targeted cancer therapies. Live webcasts of the events will be available on their website for 30 days after the presentations. This engagement indicates the company's effort to enhance investor relations.
Read more →NUVLNuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results Continued execution across pipeline with clinical trials ongoing for NVL-520 and NVL-655, and advancement of NVL-330 toward clinical
Nuvalent, Inc. has reported progress in its clinical pipeline, focusing on NVL-655, NVL-520, and NVL-330. Financial results for the second quarter of 2023 indicate a cash reserve of $431.2 million, expected to fund operations until mid-2025. Preliminary data from the ongoing ALKOVE-1 trial for NVL-655 is anticipated in the fourth quarter, reflecting positive advancements in cancer treatment solutions. However, the company reported a net loss of $29.1 million this quarter, highlighting ongoing financial challenges.
Read more →NUVLNuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has reported progress in its clinical pipeline and financial results for Q2 2023. The company is advancing its trials for NVL-520 and NVL-655, with preliminary data expected from the ALKOVE-1 study in Q4 2023. Nuvalent's cash reserves of $431.2 million are projected to sustain operations into 2025, despite a net loss of $29.1 million in the second quarter.
Read more →NUVLNuvalent to Participate in Upcoming August Investor Conferences Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. will be participating in several investor conferences in August, showcasing its focus on targeted therapies for cancer. CEO James Porter and CFO Alexandra Balcom will represent the company and their presentations will be available for streaming on the company's website. This participation is aimed at increasing investor awareness and engagement regarding their clinical-stage developments.
Read more →NUVLNuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. will participate in the TD Cowen 4th Annual Oncology Innovation Summit, scheduled for May 31, 2023. CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat, aiming to showcase the company's targeted cancer therapies. A live webcast will be available for those unable to attend in person, indicating the company's commitment to maintaining investor engagement. This participation underscores Nuvalent's positioning within the oncology space and highlights their focused development strategies.
Read more →NUVLNuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results Preliminary dose-escalation data anticipated in second half of 2023 from ongo
Nuvalent has announced that preliminary dose-escalation data for NVL-655, a novel ALK-selective inhibitor, is expected in the second half of 2023. The ongoing ALKOVE-1 Phase 1/2 trial is evaluating NVL-655 in patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The company reported a strong cash position of approximately $450.5 million, sufficient to fund operations through mid-2025. However, a net loss of $25.2 million was noted for the first quarter of 2023, along with various risks associated with the drug development process.
Read more →NUVL▲ +5.1%on this news
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced its participation in the Stifel 2023 Virtual Targeted Oncology Days. CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat scheduled for April 26, 2023. The event underscores the company's commitment to targeted therapies in cancer treatment. A live webcast of the event will be accessible on the company's website, along with an archived version available for 30 days thereafter.
Read more →NUVLNuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has presented new preclinical data for NVL-655, a brain-penetrant ALK-selective tyrosine kinase inhibitor (TKI), at the AACR Annual Meeting 2023. Designed to target ALK mutations that resist current therapies, NVL-655 showed potent effects in a model of treatment-resistant intracranial ALK-positive non-small cell lung cancer (NSCLC). The study emphasizes its unique ability to penetrate the brain while avoiding neurological side effects common with other TKIs. As NVL-655 progresses towards clinical trials, it represents a promising advancement for patients with brain metastases linked to ALK-positive NSCLC.
Read more →NUVLNuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced an upcoming poster presentation for the Phase 1/2 ALKOVE-1 study of NVL-655 at the European Lung Cancer Congress (ELCC 2023). The study evaluates the safety and preliminary activity of NVL-655, targeting solid tumors with oncogenic ALK alterations, including those with resistance mutations. The trial aims to assess NVL-655 as an oral monotherapy and is currently in the dose-escalation phase. Key insights and data will be shared during the poster presentation scheduled for March 31, 2023.
Read more →NUVL▲ +5.4%on this news
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results Significant progress made across pipeline of novel kinase inhibitors with parallel-lead programs in ongoi
Nuvalent reported significant advancements in its pipeline of novel kinase inhibitors during 2022, including positive Phase 1 clinical trial data for its lead candidates NVL-520 and NVL-655. The company maintains a strong financial position with $472 million in cash, supporting operations through the second half of 2025. Leadership changes have been announced, with key promotions aimed at enhancing the company’s strategic initiatives. Overall, Nuvalent's proactive approach and successful milestones underscore its commitment to developing targeted cancer therapies.
Read more →NUVL▲ +6.1%on this newsshared move
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. announced the upcoming presentation of preclinical data for its ALK-selective inhibitor NVL-655 at the AACR Annual Meeting 2023. This data showcases NVL-655's antitumor activity against alectinib-resistant lung cancer models, suggesting its potential to treat patients with advanced ALK-positive non-small cell lung cancer. The presentation will occur on April 18, 2023, as part of the company's ongoing clinical development efforts for NVL-655, currently evaluated in the ALKOVE-1 study.
Read more →NUVLNuvalent to Participate in the 43rd Annual Cowen Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. has announced its participation in the 43rd Annual Cowen Healthcare Conference, scheduled for March 8, 2023. CEO James Porter and CFO Alexandra Balcom will be featured in a fireside chat during the event. Investors can access a live webcast on the company's website, which will also be archived for 30 days after the presentation. The conference offers an opportunity for Nuvalent to discuss its innovative approaches to targeted therapies in oncology.
Read more →NUVLNuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. James Porter, Ph.D., the CEO, will discuss the company's targeted therapies for kinase targets in cancer. The presentation will highlight the company's focus on innovative cancer treatments and investor engagement. A live webcast will be available for those interested in the presentation and will be archived for 30 days.
Read more →NUVLNuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case studies CAMBRIDGE, Mass. , Dec. 13, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on
Read more →NUVLNuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-c
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive N
Read more →NUVL▲ +60.6%on this newsshared move
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC Favorable preliminary safety profile of NVL-520 suggests potenti
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with
Read more →NUVLNuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Preclinical data demonstrated that NVL-330 inhibits HER2 exon 20 insertion mutations, is selective for HER2 versus wild-type EGFR, and is brain-penetrant NVL-655 preclinical data further support its best-in-class potential for patients with advanced ALK-positive NSCLC and other
Read more →NUVL▲ +7%on this news
Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that management will host a live webcast an
Read more →NUVLNuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
CAMBRIDGE, Mass. , Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L. Meyers , M.D.,
Read more →NUVL▲ +17.6%on this news
Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the New Drugs on the Horizon Oral Plenary Session New...
Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical Data to be Presented on Parallel-lead, Clinical-stage Candidate NVL-655, an ALK-selective Inhibitor Selection of Third Dev
Read more →NUVLNuvalent to Participate in the Wells Fargo 2022 Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive
Read more →NUVL▲ +12.3%on this news
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-52
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors
Read more →NUVLNuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520 CAMBRIDGE, Mass. , Aug. 5, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi
Read more →NUVLNuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive O
Read more →NUVL▼ -7.9%on this news
Nuvalent Announces Leadership Promotions Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Darlene Noci , A.L.M. promoted to Chief Development Officer Benjamin Lane , Ph.D. promoted to Senior Vice President, Technical Operations CAMBRIDGE, Mass. , July 20, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creat
Read more →NUVL▲ +5.4%on this news
Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile CAMBRIDGE, Mass. , July 13, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinic
Read more →NUVL▲ +10.2%on this news· ran to +36% by day 3
Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors First patient dosed in ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with
Read more →NUVLNuvalent to Present at the 2022 Jefferies Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
CAMBRIDGE, Mass. , June 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive O
Read more →NUVLNuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection of two additional development candidates in 2022 Ended t
Read more →NUVLNuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven...
NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma NVL-655 demonstrated differentiation through broad preclinical activity across diverse ALK oncoproteins, resi
Read more →NUVLNuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL ), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive
Read more →NUVLNuvalent Appoints Anna Protopapas as Chair of Board of Directors Nuvalent, Inc. (Nasdaq: NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets...
Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass. , March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical stage biopharmaceutical company creating
Read more →NUVL▲ +7.5%on this news· ran to +20% by day 3shared move
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of
Read more →NUVLNuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today...
CAMBRIDGE, Mass. , March 8, 2022 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL ) a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced multiple preclinical data presentations supporting advancement of its par
Read more →NUVLNuvalent to Participate in the Cowen 42nd Annual Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in...
CAMBRIDGE, Mass. , March 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, will p
Read more →NUVLNuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today...
CAMBRIDGE, Mass. , Feb. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Emily Drabant Conley , Ph.D., Chief Executive Officer o
Read more →NUVLNuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today...
CAMBRIDGE, Mass. , Jan. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed in ARROS-1, its Phase 1/2 clinical t
Read more →NUVLNuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in...
CAMBRIDGE, Mass. , Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, will pr
Read more →NUVLNuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results ARROS-1 Clinical Trial of NVL-520 for the Treatment of Patients with Advanced ROS1-positive NSCLC and Other Solid Tumors is Open for Enrollment
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results ARROS-1 Clinical Trial of NVL-520 for the Treatment of Patients with Advanced ROS1-positive NSCLC and Other Solid Tumors is Open for Enrollment On-track for Initiation of Clinical Trial of NVL-655 for
Read more →NUVL▼ -6.5%on this news
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in...
CAMBRIDGE, Mass. , Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc. , (Nasdaq: NUVL ), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, provided new preclinical data on Thursday supporting advancement of its p
Read more →NUVLNuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results IND Application for NVL-520 Cleared by US FDA; Company Expects to Initiate Phase 1/2 Clinical Trial in Second Half of 2
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results IND Application for NVL-520 Cleared by US FDA; Company Expects to Initiate Phase 1/2 Clinical Trial in Second Half of 2021 $190.6 Million Upsized IPO Completed to Fund Continue
Read more →NUVL▲ +20.1%on this news· ran to +36% by day 3
Nuvalent Announces Closing of Upsized Initial Public Offering Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today...
CAMBRIDGE, Mass. , Aug. 2, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its upsized initial public offering of 11,212,500 shares of
Read more →NUVLNuvalent Announces Pricing of Initial Public Offering Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today...
CAMBRIDGE, Mass. , July 28, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its initial public offering of 9,750,000 shares of common s
Read more →NUVLNuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the...
CAMBRIDGE, Mass. , May 11, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing. The round was led by Bain Capital Lif
Read more →NUVLNuvalent Presents Preclinical Data Demonstrating That ROS1 Inhibitor NUV-520 and ALK Inhibitor NUV-655 are Selective, Brain-Penetrant, and Active Against Drug-Resistance Mutations Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced...
CAMBRIDGE, Mass. , April 10, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preclinical data supporting advancement of its parallel lead programs in non-small cell
Read more →NUVLNuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the...
CAMBRIDGE, Mass. , March 23, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner , M.D., as Chief Medical Officer. Dr. Turner bring
Read more →NUVLNuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced a $50M...
CAMBRIDGE, Mass. , Jan. 27, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced a $50M Series A financing from Deerfield Management. The company also announced its launc
Read more →Competitive Position
How NUVL ranks across every disease it competes inCompetitive Position is a premium feature
See how NUVL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial